Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of AG-120 in IDH1 Mutant Chondrosarcoma

NCT04278781 is registered in ClinicalTrials.gov with Memorial Sloan Kettering Cancer Center as lead sponsor.

NCT NCT04278781
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04278781 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of AG-120 in IDH1 Mutant Chondrosarcoma
Lead sponsor
Memorial Sloan Kettering Cancer Center
Phase
Phase 2
Overall status
Active, not recruiting
Start date
March 4, 2020
Completion date
March 31, 2027
Enrollment
6 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

chondrosarcoma, chondrosarcoma, grade 2, chondrosarcoma, grade 3, idh1 gene mutation